MARKET

LCTX

LCTX

Lineage Cell Therapeutics Inc
AMEX

Real-time Quotes | Nasdaq Last Sale

2.670
-0.010
-0.37%
Opening 11:37 07/23 EDT
OPEN
2.700
PREV CLOSE
2.680
HIGH
2.715
LOW
2.650
VOLUME
526.20K
TURNOVER
--
52 WEEK HIGH
3.132
52 WEEK LOW
0.7850
MARKET CAP
432.92M
P/E (TTM)
-29.4377
1D
5D
1M
3M
1Y
5Y
Lineage Cell's Dry AMD Gene Therapy Demonstrate Functional, Anatomical Improvements
Benzinga · 2d ago
BRIEF-Lineage Cell Therapeutics Says Intends To Meet With FDA On Clinical Development Plan For Opregen
reuters.com · 3d ago
Lineage Cell Therapeutics Reports Updated Interim Results From Ongoing, 24-Patient Phase 1/2a Clinical Study Of Its Lead Product Candidate, OpRegen: 83% Of Cohort 4 Patients' Treated Eyes Continued To Be At Or Above Baseline
Eighty-Three Percent of All Cohort 4 Patients Continued to Exhibit Stable or Improved BCVA At Least 6 Months Post-Treatment; Visual Acuity Declined in the Majority of Untreated Eyes Three Patients with Evidence of
Benzinga · 3d ago
OpRegen® Clinical Data Continues to Demonstrate Functional and Anatomical Improvements in Patients With Dry AMD With Geographic Atrophy
CARLSBAD, Calif., July 20, 2021--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported updated interim results from its ongoing, 2...
Business Wire · 3d ago
Lineage Cell Therapeutics Inc (LCTX) President and CEO Brian M Culley Sold $1.3 million of Shares
GuruFocus News · 07/01 11:15
Lineage Cell Therapeutics Joins Russell 3000® and Russell Microcap® Indexes
CARLSBAD, Calif., June 28, 2021--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that the Company has been added to both th...
Business Wire · 06/28 12:00
Insider Trends: Insider at Lineage Cell Therapeutics Converts Options in Mist of 90-Day Buying Trend
MT Newswires · 06/23 13:17
Lineage’s OPC1 cell therapy for spinal cord injury to return to clinical testing
Lineage Cell Therapeutics (LCTX) perks up 3.7% premarket after providing an update on the clinical advancement of OPC1, its investigational allogeneic oligodendrocyte progenitor cell transplant therapy for the treatment of spinal cord injury ((SCI)).Follow...
Seekingalpha · 06/22 13:28
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of LCTX. Analyze the recent business situations of Lineage Cell Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average LCTX stock price target is 5.77 with a high estimate of 8.60 and a low estimate of 4.000.
EPS
Institutional Holdings
Institutions: 118
Institutional Holdings: 66.40M
% Owned: 40.95%
Shares Outstanding: 162.14M
TypeInstitutionsShares
Increased
29
919.96K
New
11
1.63M
Decreased
26
988.89K
Sold Out
19
1.29M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.01%
Pharmaceuticals & Medical Research
+0.53%
Key Executives
Chairman/Director
Alfred Kingsley
Chief Executive Officer/Director
Brian Culley
Chief Financial Officer/Chief Accounting Officer
Kevin Cook
Finance Director/Controller
Alexandra Hernandez
Senior Vice President
Gary Hogge
Independent Director
Dipti Amin
Independent Director
Deborah Andrews
Independent Director
Don Bailey
Independent Director
Neal Bradsher
Independent Director
Anula Jayasuriya
Independent Director
Michael Mulroy
Independent Director
Angus Russell
No Data
About LCTX
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing cell therapies for unmet medical needs. It is focused on developing therapies for degenerative retinal diseases, neurological conditions associated with demyelination and aiding the body in detecting and combating cancer. Specifically, it is testing therapies to treat dry age-related macular degeneration, spinal cord injuries and non-small cell lung cancer. It has three allogeneic cell therapy programs: OpRegen, OPC1 and VAC2. OpRegen is a retinal pigment epithelium cell replacement therapy being developed for the treatment of advanced dry age-related macular degeneration (AMD) with geographic atrophy. OPC1 is an oligodendrocyte progenitor cell therapy that is being developed for acute spinal cord injuries (SCI). VAC2 is a cancer immunotherapy of antigen-presenting dendritic cells that is being developed for non-small cell lung cancer.

Webull offers kinds of Lineage Cell Therapeutics Inc stock information, including AMEX:LCTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LCTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LCTX stock methods without spending real money on the virtual paper trading platform.